Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 14/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | USP2 | O75604 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
| ▸ | NCEH1 | Q6PIU2 | 1/20 | 0.33 |
| ▸ | BACE2 | Q9Y5Z0 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17794224 | 0.89 | BACE1 (0.44) | BACE1SMN1; SMN2ALDH1A1TDP1BACE2 | |
| SCHEMBL7930223 | 0.87 | BACE1 (0.37) | BACE1SMN1; SMN2ALDH1A1TDP1BACE2 | |
| SCHEMBL9913405 | 0.85 | BACE1 (0.53) | BACE1BACE2 | |
| SCHEMBL2632264 | 0.85 | SMN1; SMN2 (0.39) | BACE1SMN1; SMN2ALDH1A1TDP1USP2 | |
| SCHEMBL1935410 | 0.84 | BACE1 (0.50) | BACE1BACE2 | |
| SCHEMBL14716596 | 0.75 | BACE1 (0.61) | BACE1BACE2 | |
| SCHEMBL17794275 | 0.74 | BACE1 (0.40) | BACE1SMN1; SMN2ALDH1A1TDP1BACE2 | |
| SCHEMBL18133256 | 0.74 | BACE1 (0.44) | BACE1ALDH1A1BACE2 | |
| SCHEMBL1934384 | 0.74 | BACE1 (0.47) | BACE1BACE2 | |
| SCHEMBL1935428 | 0.74 | BACE1 (0.47) | BACE1BACE2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8198269-B2 | Fused aminodihydrothiazine derivative | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2012-06-12 | — | — | US | disclosed |
| US-20110207723-A1 | NOVEL FUSED AMINODIHYDROTHIAZINE DERIVATIVE | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2011-08-25 | — | — | US | disclosed |
| US-20100093999-A1 | NOVEL FUSED AMINODIHYDROTHIAZINE DERIVATIVE | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2010-04-15 | — | — | US | disclosed |
| WO-2010038686-A1 | NOVEL FUSED AMINODIHYDROTHIAZINE DERIVATIVE | エーザイ・アール・アンド・ディー・マネジメント株式会社 (JP) | 2010-04-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100093999-A1 | NOVEL FUSED AMINODIHYDROTHIAZINE DERIVATIVE | BACE1, BACE2, APP | BACE1 1/4885SMN1; SMN2 1838/4885ALDH1A1 2506/4885 |
| US-20110207723-A1 | NOVEL FUSED AMINODIHYDROTHIAZINE DERIVATIVE | BACE1, APP, BACE2 | BACE1 1/4885SMN1; SMN2 2806/4885ALDH1A1 1687/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.